Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.

Mueller, Kelly L.
Madden, Julie M.
Zoratti, Gina L.
Kuperwasser, Charlotte.
List, Karin.
Boerner, Julie L.
2012

Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have shown clinical efficacy in lung, colon, and pancreatic cancers. In lung cancer, resistance to EGFR TKIs correlates with amplification of the hepatocyte growth factor (HGF) receptor tyrosine kinase Met. Breast cancers do not respond to EGFR TKIs, e... read more

Permanent URL
http://hdl.handle.net/10427/010059
Original publication
Mueller, Kelly, Julie M. Madden, Gina L. Zoratti, Charlotte Kuperwasser, Karin List, and Julie L. Boerner. "Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met." Breast Cancer Research 14, no. 6 (8, 2012): 1-11.
ID: tufts:17551
To Cite: DCA Citation Guide
Usage: Detailed Rights